Flexion Therapeutics (FLXN) in Focus: Stock Moves 10.4% Higher

Flexion Therapeutics, Inc. FLXN was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 24.7% in the past one-month time frame.

The stock gained after FDA approved its non-opioid knee pain medication.

The company has seen two negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Flexion Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.  

Flexion Therapeutics, Inc. Price

Flexion Therapeutics, Inc. Price | Flexion Therapeutics, Inc. Quote

A better-ranked stock in the Medical - Drugs industry is Corbus Pharmaceuticals Holdings, Inc. CRBP, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is FLXN going up? Or down? Predict to see what others think: Up or Down

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Flexion Therapeutics, Inc. (FLXN) : Free Stock Analysis Report
 
Corbus Pharmaceuticals Holdings, Inc. (CRBP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research